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ABSTRACT 
Uniparental disomy (UPD) testing is currently recommended during pregnancy in fetuses 
carrying a balanced Robertsonian translocation (ROB) involving chromosome 14 or 15, both 
chromosomes containing imprinted genes. The overall risk that such a fetus presents a UPD has 
been previously estimated to be around 0.6-0.8%. However, because UPD are rare events and 
this estimate has been calculated from a number of studies of limited size, we have reevaluated 
the risk of UPD in fetuses for whom one of the parents was known to carry a nonhomologous 
ROB (NHROB). We focused our multicentric study on NHROB involving chromosome 14 
and/or 15. A total of 1747 UPD testing were performed in fetuses during pregnancy for the 
presence of UPD(14) and/or UPD(15). All fetuses were negative except one with a UPD(14) 
associated to a maternally inherited rob(13;14). Considering these data, the risk of UPD following 
prenatal diagnosis of an inherited ROB involving chromosome 14 and/or 15 could be estimated 
to be around 0.06%, far less than the previous estimation. Importantly, the risk of miscarriage 
following an invasive prenatal sampling is higher than the risk of UPD. Therefore, we do not 
recommend prenatal testing for UPD(15)mat, UPD(14)mat, UPD(14)pat for these pregnancies 
and parents should be reassured. Sonographic examination will help detecting the extremely rare 
fetuses with Prader-Willi, Kagami-Ogata or Temple syndrome. Given the fact that no 
sonographic features can reliably detect fetuses with Angelman syndrome, a prenatal invasive 
sampling to test UPD(15)pat could be discussed with future parents. 
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Introduction 
Uniparental disomy (UPD) occurs when both copies of a chromosome, or part of a 
chromosome, are derived from a single parent. UPD is called heterodisomy when a pair of non-
identical chromosomes is inherited from one parent or isodisomy when a single chromosome 
from one parent is duplicated. UPD may have clinical relevance for several reasons. Isodisomy 
leads to large blocks of homozygosity, which may lead to the uncovering of recessive alleles. 
Either isodisomy or heterodisomy can disrupt parent-specific imprinted genes, resulting in 
imprinting disorders, among them the well-known Prader-Willi (PWS; OMIM 176270) and 
Angelman (AS; OMIM 105830) syndromes for chromosome 15. PWS is characterized by short 
stature, obesity, hypogonadism, and learning difficulty. Approximately 70% of individuals with 
PWS carry a microdeletion at 15q11q13 of the paternally derived homolog. Most (25 %) of the 
remaining patients with PWS have maternal UPD(15). AS is characterized by severe learning 
difficulties, epilepsy and ataxic gait. Approximately 70% of individuals with AS carry an 
interstitial microdeletion of the same 15q11q13 region as in PWS, but in this case on the 
maternally derived homolog. About 2% of the remaining patients present paternal UPD(15). 
Three different mechanisms explain UPD: (i) trisomy rescue (ii) monosomy rescue and 
(iii) gametic complementation [1]. However, the main mechanism responsible for UPD is trisomy 
rescue mostly related to advanced maternal age [2]. This is highlighted by the higher proportion 
of maternal UPD to the etiology of PWS compared to that of paternal UPD to the etiology of AS 
(25% versus 2%). Apart advanced maternal age, any condition predisposing to aneuploid gametes 
increases the risk for UPD. Therefore, individuals carrying a balanced Robertsonian translocation 
(ROB) have an increased risk of aneuploid embryos, miscarriages and UPD following trisomy 
rescue. 
UPD testing is currently recommended in fetuses carrying a balanced ROB involving 
chromosome 14 or 15 [1]. Thus, most of the cytogenetic laboratories follow this 
recommendation and some of them attempted to estimate the risk of UPD following prenatal 
diagnosis of a ROB involving chromosome 14 or 15 [3,4,5,6,7,8]. From these combined data, the 
overall risk that a fetus with a non-homologous ROB (NHROB) presents a UPD has been 
estimated to be around 0.6-0.8% [9]. However, because UPD are rare events and this estimate 
has been calculated from a number of studies of limited size, we have reevaluated the risk of 
UPD in fetuses for whom one of the parents was known to carry a NHROB. We focused our 
multicentric study on NHROB involving chromosome 14 and/or 15, the two chromosomes 
containing imprinted genes involved in ROB. 
 
Patients and Methods 
Data were collected from 28 French genetic laboratories, all members of the “Association 
des Cytogénéticiens de Langue Française (ACLF; the French-Speaking Cytogeneticists 
Association)” and/or the Association Nationale des Praticiens en Génétique Moléculaire 
(ANPGM; National Association of Molecular Genetics Practitioners). The current study was set 
up to gather the results of UPD survey, over more than 10 years, in prenatal period. The study 
followed the local ethical guidelines of CHU Nantes, France. The study was reviewed and 
approved by the Board of the ACLF. 
The genetic laboratories provided the results of UPD(14) and UPD(15) testing in fetuses 
for whom one of the parents was known to carry a NHROB. Fetal karyotype was obtained from 
amniotic fluid and/or chorionic villi samples. Eight laboratories also provided the results of UPD 
testing performed in fetuses with normal karyotype but conceived by a parent carrying a 
NHROB. 
UPD tests were performed using different methods depending on the chromosome 
involved. UPD(15) tests were carried out using MS-MLPA Probemix (ME028, Prader-
Willi/Angelman) from MRC Holland according to the manufacturer's protocol or using custom 
sets of microsatellite genetic markers (short tandem repeats). UPD(14) tests were performed 
using the Epitect bisulfite kit Qiagen ® enabling the study of the methylation status of MEG3 
(Maternally Expressed Gene) on chromosomal region 14q32.2 followed by confirmation with 
microsatellite genetic markers on chromosome 14 for positive cases. 
 
Results 
Twenty-eight genetic laboratories participated to this retrospective study. A total of 1747 UPD 
diagnoses were performed. 
We obtained additional data for 832 fetuses among them 661 inherited the balanced 
NHROB while 171 had a normal karyotype. Thus, the chromosomes involved in the 
translocation were obtained for 661 fetuses as well as the sex of its carrier parent (table 1). No 
significant difference was observed in the sex of the carrier parent (336 translocations were 
present in the father and 325 in the mother). As expected, the most frequent translocation was 
the rob(13;14) (394 fetuses among 661) followed by the rob(14;21) (112 fetuses among 661). The 
other translocations (i.e. rob(14;15) rob(14;22), rob(13;15), rob(15;21) and rob(15;22)) were 
observed in the remaining 115 fetuses. 
 
 
Table 1: Type of  Robertsonian translocation and parental origin 
 
Fetal NHROB Paternal Maternal 
rob(13;14) 205 189 
rob(14;15) 35 17 
rob(14;21) 54 58 
rob(14;22) 7 21 
rob(13;15) 18 13 
rob(15;21) 8 11 
rob(15;22) 9 16 
Total 336 325 
 
Among the 1747 fetuses diagnosed for UPD, 686 were tested for UPD(15) and 1061 for 
UPD(14). No fetuses showed UPD(15). Only one fetus out of 1061 showed UPD(14) of 
maternal origin. The fetal karyotype was 45,XX,rob(13;14)(q10;q10) and the translocation was 
inherited from her 28-year-old mother. Intrauterine growth retardation was noted during 
pregnancy. After genetic counseling the parents decided to continue the pregnancy. A girl was 
born at 40 weeks of gestation. Birth parameters were less than 10th percentile (weight 2965 g and 
length 46 cm). The child was not available for postnatal follow up.  
 Among the 171 fetuses with normal karyotype but conceived by a ROB carrier parent, 
none of them showed UPD for chromosome 14 or 15. 
 
Discussion 
The concept of UPD was first introduced by Eric Engel in 1980 when he hypothesized that 
patients might present a genetic disorder caused by the presence of two copies of the same 
homolog inherited from only one of their parents [10]. As explained in his memories, his paper 
“slept on a shelf for several years waiting for more evolution in molecular techniques to be able 
to study the parental origin of chromosomes from their DNA polymorphisms” [11,12] 
Warburton D. 1988 AJHG 1988;42:215-216). Finally, proof of concept was achieved after 
publication of a patient with cystic fibrosis [13]. Only one of his parents was carrying a 
heterozygous pathogenic variant in the CFTR gene, the patient carried the variant in a 
homozygous state resulting from an isodisomy of chromosome 7 of maternal origin. Afterwards, 
during the late 1980s and early 1990s, the first patients with PWS and AS caused by maternal and 
paternal UPD(15), respectively, and patients with Temple Syndrome (OMIM 616222) and 
Kagami-Ogata syndrome (OMIM 608149) caused by maternal and paternal UPD(14), 
respectively, were reported [14,15]. For those cases, the UPD was suspected since the patient was 
a carrier of a balanced ROB involving either chromosome 15 or 14 inherited from a healthy 
carrier parent.  
After these first descriptions, several teams reported patients with UPD(14) or UPD(15) 
[16,17,18,19] likely corresponding to the unsolved cases left in drawers for a very long time. 
Overall, thirty years after proof of concept of UPD, very few cases of UPD(14) and UPD(15) 
associated to an inherited NHROB involving chromosome 14 or 15 have been reported. Among 
more than 600 cases of UPD(14) and UPD(15) registered in a regularly updated database, only 31 
cases are associated to a NHROB, of which 20 cases are de novo and 11 are inherited (Pr. Thomas 
Liehr, Jena lab-Germany http://upd-tl.com/upd.html and [20]. Of note, these combined data 
suggest that the risk of UPD is significantly higher when the translocation is de novo in the fetus 
than when it is inherited from a carrier parent (twice more frequent). Most of these patients are 
case reports and cannot be used to estimate the risk of UPD for a fetus conceived by a ROB 
carrier (table 2). 
Table 2: Studies estimating the number of  fetuses with UPD and an inherited or a 
de novo NHROB  
 
 
Nbr 
fetus 
Nbr of UPD cases associated 
to an inherited ROB 
Nbr of UPD cases associated to a de novo 
ROB 
Series    
Sensi A. 
(2004) 
160 One case of UPD(14)mat, 
rob(14;22)mat 
 
Silverstein 
S. (2002) 
42  one case of upd(14)mat, rob(13;14)dn 
Ruggeri A. 
(2004)    
83  one case of upd(14)mat, rob(14;21)dn 
Jay AM. 
(2001) 
22   
Barton DE. 
(1996)                  
14  one case of upd(14)mat, rob(13;14)dn 
Kotzot D. 
(2000)                    
458  Six cases of  UPD  
 779 One case of UPD associated 
to an inherited ROB (0.13%) 
9 cases of UPD (UPD risk 1.16%)   
 
 
In 2006, Lisa G. Shaffer combined the published data and estimated the risk of UPD 
when a balanced NHROB (de novo or inherited) is detected in a fetus to be around 0.6-0.8% (3 
fetuses with UPD among 477 fetuses studied). Two UPD were identified in fetuses carrying a de 
novo ROB while one fetus inherited the balanced ROB from a parent. Therefore, the estimated 
risk of UPD associated to an inherited ROB is approximately 0.2% (1/477 fetuses). This risk is 
likely overestimated since only one negative cohort was included, other negative cohorts might 
have been unpublished [6]. In our ten years retrospective study involving 28 genetic diagnostic 
laboratories, >1500 fetuses carrying a ROB inherited from a healthy parent were tested during 
pregnancy for the presence of UPD(14) and/or UPD(15). All fetuses were negative except one 
with a UPD(14)mat associated to an inherited rob(13;14). The risk of UPD following prenatal 
diagnosis of an inherited ROB involving chromosome 14 and/or 15 could be estimated around 
0.06%, far less than the previously estimation of 0.6%. Importantly, this estimated risk of 0.06% 
is less than the risk of miscarriage following invasive fetal sampling, despite the fact that this 
estimated risk of miscarriage is still controversial (reevaluated by Akolekar R. (2015)[21]. Until 
recently, when a parent was carrying a ROB involving chromosomes 13 or 21, an invasive fetal 
sampling was discussed to exclude a trisomy 13 or 21. If the ROB involved chromosomes 14 or 
15, UPD testing was performed at the same time as karyotyping. Currently, non-invasive prenatal 
diagnosis (NIPT) is replacing this invasive procedure. Therefore, the only purpose of an invasive 
procedure would be UPD testing. 
UPD following monosomy rescue are rarely observed probably because the embryo does 
not survive enough to duplicate the autosome and become isodisomic [9]. To the best of our 
knowledge, only two patients conceived by a ROB carrier were reported postnatally with UPD 
following monosomy rescue. Recently, Bramswig NC et al. reported a patient with AS caused by 
UPD(15) and a normal karyotype. The two paternal chromosomes 15 were inherited from his 
healthy father. The mother was a carrier of a balanced rob(14;15) [22]. The second patient is a girl 
presenting with polyhydramnios, short limbs and small thorax during pregnancy [23]. After 
delivery, a UPD(14)pat was diagnosed explaining the clinical features in this child with a normal 
karyotype (46,XX). Familial study showed that her mother is carrier of a rob(13;14). In most 
laboratories participating in the present study, diagnosis of UPD was carried out if a balanced 
ROB was detected in the fetus. However, in eight laboratories, all pregnancies conceived with 
one of the parents carrier of a balanced ROB were tested for UPD regardless of fetal karyotype 
(carrying the balanced ROB or not). No UPD(14) or UPD(15) was detected in 171 fetuses with 
normal karyotype which is in agreement with the rare risk of UPD following monosomy rescue. 
[5] also studied 18 fetuses with a normal karyotype but conceived by a parent carrying a ROB to 
evaluate the risk of monosomy rescue and did not identified any UPD. These results confirm that 
UPD following a monosomy rescue is extremely rare.  
Another mechanism leading to UPD is gametic complementation. This mechanism is 
extremely rare and not easy to prove unless there is a structural chromosomal anomaly. Up to 
now, two cases of gametic complementation have been well documented. Cotter PD et al (1997) 
[24] reported a patient presenting with Kagami-Ogata syndrome (OMIM 608149) due to a 
UPD(14)pat. The parents of the patient were carriers of two different Robertsonian 
translocations, the mother with rob(14;21) and the father with rob(13;14). These two parental 
translocations favor the fertilization of a nullisomic gamete for chromosome 14 with a disomic 
one. Such observation was also observed in another case of Kagami-Ogata syndrome with 
parents both carriers of chromosomal translocations: the father with rob(13;14) and mother 
carrier of a reciprocal translocation t(1;14)(q32;q32) [25]. When both parents carry a 
chromosomal translocation involving chromosomes 14 and/or 15, the risk of UPD is highly 
increased and a prenatal UPD test should be considered. 
Our data show that the risk of UPD following prenatal diagnosis in a fetus who inherited 
ROB involving chromosome 14 and/or 15 is very low. Therefore, if prenatal UPD testing is not 
done, what is the risk of misdiagnosis of fetal UPD(14) or UPD(15)? During pregnancy, most 
fetuses with Prader-Willi, Kagami-Ogata or Temple syndrome present abnormal features which 
can be detected by ultrasound examination. Gross N et al (2015) [26] performed a retrospective 
study on the prenatal ultrasound records of 106 patients with PWS diagnosed postnatally. In this 
study, the following ultrasound features were studied: small for gestational age (SGA, 10 
centile), asymmetrical intrauterine growth, polyhydramnios and breech position. The authors 
showed that 98% of the fetuses with PWS presented at least one of these ultrasound features 
during pregnancy. 
In postnatal, patients with Kagami-Ogata syndrome (OMIM 608149) present with 
feeding difficulties, development delay, intellectual disability and skeletal abnormalities especially 
a bell-shape thorax and increased coat-hanger angle. In a review, UPD(14)pat was detected in 
23/34 patients showing that UPD is a common mechanism leading to the syndrome. In prenatal 
period, ultrasound signs are almost always observed. The most common fetal ultrasound signs are 
particular thorax abnormalities small bell-shaped thorax and an abnormal coat-hanger appearance 
observed in all cases. Polyhydramnios, requiring one or more amnioreduction, is also reported in 
all cases. In more than 80% of fetuses, a placentomegaly could also be detected [27]. The 
association of the these signs is considered a hallmark for UPD(14)pat in prenatal period. 
Thirty-two patients with Temple Syndrome (TS14, OMIM 616222) have been reported 
[28]. The main features in postnatal period are growth failure, hypotonia, small hands and feet, 
precocious puberty. Intellectual disability is not frequent. UPD is also a common mechanism 
leading to the syndrome since 23/32 patients presented with UPD(14)mat. In prenatal period, 
90% of the fetuses present an IUGR (a mean of -2.2 SD). A hypoplastic placenta can also be 
observed.  
Taken together, these data show that at least one abnormal sonographic feature is 
detected in the majority of the fetuses with Prader-Willi, Kagami-Ogata or Temple syndrome 
[26,27,28 and table 3]. In the context where a parent is a carrier of a ROB involving chromosome 
14 or 15, the detection during pregnancy of a single abnormal ultrasound finding should lead to a 
prenatal testing for UPD. 
Table 3: Prenatal features in fetuses with UPD(14) or UPD(15) 
UPD  
dup(14)pat 
Kagami Syndrome 
dup(14)mat 
Temple 
syndrome 
dup(15)mat 
Prader Willi 
Syndrome 
dup(15)pat 
Angelman 
Syndrome 
Ultrasonographic 
signs 
Small bell-shaped 
thorax with coat-
hanger appearance 
of the ribs and 
Polyhydramnios (all 
cases) 
RCIU 
(Almost all 
cases 97%) 
Polyhydramnios,  
Decreased fetal 
movement 
Breech presentation 
Mild prenatal growth 
retardation 
2% of cases present 
no ultrasonographic 
sign 
No 
ultrasonographic 
sign 
Regarding AS, which can be caused by UPD(15)pat, there are no ultrasound features in 
an affected fetus which could reliably lead to a suspicion of this syndrome and a prenatal 
diagnosis. Therefore, a prenatal testing for UPD(15)pat could be proposed (Clinical and genetic 
aspects of Angelman syndrome, [29]. Nevertheless, to the best of our knowledge, no patients 
with AS associated to a UPD, diagnosed following a prenatal testing triggered by a parental ROB 
involving chromosome 15, have been reported. Likewise, no UPD(15)pat has been detected in 
our series of 686 tests. 
In conclusion, we estimate the risk of UPD when a parent is carrier of a NHROB 
involving chromosome 14 and/or 15 to be about 0.06%, ten times less than the previously 
published estimation. The risk of miscarriage following an invasive prenatal sampling is higher 
than the risk of UPD. Therefore, we do not recommend prenatal testing for UPD(15)mat, 
UPD(14)mat, UPD(14)pat in this context and parent should be reassured. Sonographic 
examination will help detecting the extremely rare fetuses with Prader-Willi, Kagami-Ogata or 
Temple syndrome. Given the very low risk of UPD following malsegregation/rescue, a prenatal 
invasive sampling to test UPD(15)pat responsible for Angelman Syndrome could however be 
discussed with future parents. 
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